Open an account

Chemomab Therapeutics

CMMB · NASDAQ

$1.18+$0.01 (+0.85%)TodayMarket closed ·
Prev close $1.17

About CMMB

Chemomab Therapeutics Ltd. is a clinical-stage biotech company, which engages in the provision of therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company employs 12 full-time employees The company went IPO on 2012-08-14. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Employees
12
Headquarters
TEL AVIV-YAFO
Listed
Aug 14, 2012
Sector
Health Care
Industry
Biotechnology
Website
chemomab.com

CMMB key statistics

Market cap
8.48M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
107.32K
Volume
64.83K
Open price
$1.19
High today
$1.29
Low today
$1.17
52 Week high
$3.45
52 Week low
$1.05

Chemomab Therapeutics (CMMB) at a glance

Chemomab Therapeutics (CMMB) last traded at $1.18, with a market cap of 8.48M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.17 and $1.29. The current price is 0.9% above the day's low and 8.5% below its high.

Volume so far is 64.83K shares, below the average of 107.32K shares a day.

Over the past year Chemomab Therapeutics has ranged from $1.05 to $3.45, and now sits 5% of the way up that range.

Chemomab Therapeutics met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$0.24 per share against an estimate of -$0.153.

CMMB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 24.1% on average.

  1. Q1 FY24: reported -$0.28 per share against an estimate of -$0.0204
  2. Q2 FY24: reported -$1.04 per share against an estimate of -$0.0571
  3. Q3 FY24: reported -$0.80 per share against an estimate of -$0.0245
  4. Q4 FY24: reported -$0.64 per share against an estimate of -$0.3182
  5. Q1 FY25: reported -$0.56 per share against an estimate of -$0.0408
  6. Q4 FY25: reported -$0.24 per share against an estimate of -$0.3162
  7. Q1 FY26: reported -$0.24 per share against an estimate of -$0.1581
  8. Q2 FY26: reported -$0.24 per share against an estimate of -$0.153

CMMB news

  • Press releaseGlobe Newswire

    Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseGlobe Newswire

    Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

  • Market-Moving News for February 19th

  • Press releaseGlobe Newswire

    Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

  • Press releaseGlobe Newswire

    Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Similar companies

Companies in the same industry as Chemomab Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.